Elazig Education and Research Hospital, Department of Dermatology, Elazig, Turkey.
J Dermatolog Treat. 2012 Dec;23(6):410-20. doi: 10.3109/09546634.2011.590788. Epub 2011 Jul 25.
Alopecia areata (AA) is a non-scarring hair loss.
We aimed the comparison of clobetasol propionate and pimecrolimus efficiency and tolerability in the treatment of AA.
The study included a total of 100 consecutive patients with AA. Patients were randomized into four groups. 30 patients used 1% pimecrolimus cream, 30 patients used 0.05% clobetasol propionate cream, 20 patients used petrolatum as placebo. Scalp of 20 patients was divided into two equal areas and one area was treated with 1% pimecrolimus cream and the other area with 0.05% clobetasol propionate cream.
At week 12 of treatment, the recovery rate of the pimecrolimus group was 53.73 ± 44.49 and the recovery score was 3.63 ± 2.07; that of the clobetasol propionate group was 47.00 ± 44.80 and the recovery score was 3.33 ± 2.20; that of the placebo group was 35.50 ± 40.53 and the recovery score was 2.75 ± 1.88. There was no statistically significant difference among the groups in terms of the percentage of recovery and the recovery score (p < 0.05).
In conclusion, we detected that topical pimecrolimus treatment is as effective as topical corticosteroids and is superior to topical corticosteroids in terms of side effects in the treatment of AA.
斑秃是一种非瘢痕性脱发。
比较丙酸氯倍他索和吡美莫司治疗斑秃的疗效和耐受性。
本研究共纳入 100 例连续斑秃患者。患者随机分为四组。30 例患者使用 1%吡美莫司乳膏，30 例患者使用 0.05%丙酸氯倍他索乳膏，20 例患者使用凡士林作为安慰剂。将 20 例患者的头皮分为两个相等的区域，一个区域用 1%吡美莫司乳膏治疗，另一个区域用 0.05%丙酸氯倍他索乳膏治疗。
治疗 12 周时，吡美莫司组的恢复率为 53.73%±44.49%，恢复评分为 3.63±2.07；丙酸氯倍他索组为 47.00%±44.80%，恢复评分为 3.33±2.20%；安慰剂组为 35.50%±40.53%，恢复评分为 2.75±1.88%。三组间恢复率和恢复评分差异无统计学意义（p>0.05）。
总之，我们发现局部吡美莫司治疗与局部皮质类固醇一样有效，且在治疗斑秃方面副作用优于局部皮质类固醇。
